|
Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA). |
|
|
Honoraria - AstraZeneca; Janssen; Novartis; Taiho Pharmaceutical |
Consulting or Advisory Role - AstraZeneca; Janssen; Novartis; Taiho Pharmaceutical |
|
|
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Genentech/Roche; Onyx |
Research Funding - Abbvie (Inst); Bayer (Inst); Exelixis (Inst); Gilead Sciences (Inst); MedImmune (Inst); OncoMed (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
|
|
Honoraria - Boehringer Ingelheim |
Consulting or Advisory Role - Abbvie; Bayer; Boehringer Ingelheim; Celgene; Clovis Oncology; Genentech/Roche; GlaxoSmithKline; Helsinn Therapeutics; Novartis |
Research Funding - Abbvie (Inst); Bayer (Inst); GlaxoSmithKline (Inst); MethylGene (Inst) |
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Celgene; Genentech; GlaxoSmithKline; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda |